NCT01182142已完成2 期
Phase II Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma Patients
Kidney Cancer Research Bureau1 个研究点 分布在 1 个国家目标入组 51 人开始时间: 2007年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 51
- 试验地点
- 1
- 主要终点
- Overall response rate
研究概览
简要总结
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. The role of capecitabine in treatment of metastatic renal cell carcinoma is discussed. In this trial, we are evaluating efficacy of capecitabine in metastatic renal cell carcinoma patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •histologically confirmed non-clear cell renal cell carcinoma
- •confirmed metastatic sites
- •no chemotherapy in history
排除标准
- •metastases in CNS
- •previous targeted therapy
- •other tumor
研究组 & 干预措施
Capecitabine
Experimental
All patients will receive capecitabine.
干预措施: Capecitabine (Drug)
结局指标
主要结局
Overall response rate
时间窗: 12 months
次要结局
- Overall survival Progression-free survival(24 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Capecitabine For Nasopharyngeal CancerHead and Neck CancerNCT00095901Dana-Farber Cancer Institute3
招募中
2 期
Phase II study of chemotherapy with Capecitabine/Bevacizumab in elderly patients with advanced and recurrent colorectal cancerJPRN-UMIN000010200Yamafuchi University Medical Bioregulation Department of Organ Regulatory Surgery30
已完成
不适用
Phase II trial of capecitabine for brain metastasis of breast cancerbrain metastasis of breast cancerJPRN-UMIN000001530ational cancer center hospital32
进行中（未招募）
不适用
Phase II-Studie: Standardchemotherapie Capecitabin in Kombination mit Bevacizumab in der Erstlinientherapie beim metastasierten kolorektalen Karzinom - AIO KRK 0105EUCTR2005-001919-21-DEMartin-Luther-Universität Halle-Wittenberg, Medizinische Fakultät, endvertreten durch den Dekan80
终止
2 期
CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomasNeuroendocrine CarcinomaNCT03387592Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori53